As most parts of the world still do not have COVID enhancers, a new Israeli study highlights the urgency of releasing a third dose of the vaccine.
Considerable research has shown that both the quantity and quality of antibodies rise to the sky after the third dose of Pfizer vaccine. Although the study has limited relevance given the third doses already given in Israel and other western countries, it has broader global significance.
Worldwide, only 24 people donated 24 stimulants – disproportionate in rich countries.
In Africa, only 1.6 stimulants per 100 people were provided; In India, amplifiers were only available last month, a figure of 2; and in Russia it is 9.7, and in all these places there are many people who have already been vaccinated for the first time.
A new study, published in the journal Nature Immunology and based on 12,413 staff at Sheba Medical Center, Israel’s largest hospital, found that IgG levels, one of the main types of antibodies, increased by an average of 1.7 times after the third dose. increases after the second dose. The biggest growth was among young and healthy people.
He also found that the strength or effectiveness of the antibodies was much higher after the third shot than after the second shot. The study also confirms the scientists’ assumption that high antibodies protect against infection, so measuring antibody levels is a good guide to assessing the level of protection. He found that “progressive” infections, which mean infections after vaccination or recovery, were more common in people with low antibody levels.
The authors, led by Dr. Gili Regev-Yochai, director of the epidemiological department of Sheba, said, “At least 5 months after the second dose, [a third dose] safely enhances protection against SARS-CoV-2 infection by significantly inducing induced broad humoral and cellular responses. Humoral responses are reactions in body fluids.
Research is important, prof. Kirill Cohen, an immunologist at Bar Ilan University, did not attend.
“Although several studies have documented the effectiveness of a third dose of mRNA vaccine compared to two doses, this new study actually provides direct and realistic data on antibody levels among hundreds of subjects,” he told The Times of Israel.
“This work provides a mechanical understanding of how these vaccines work. For example, after the third dose, not only will the number of antibodies increase, but their quality or susceptibility will also increase. This is important and useful for health authorities to plan. Vaccine strategies.”